Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 7Glioma 6Gliosarcoma 5Brain Neoplasms 4Neuroblastoma 3Diffuse Intrinsic Pontine Glioma 3Recurrence 2Ovarian Neoplasms 2Oligodendroglioma 2Lymphoma 2Central Nervous System Neoplasms 2Carcinoma, Renal Cell 2Astrocytoma 2Wilms Tumor 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Stomach Neoplasms 1Spinal Cord Neoplasms 1Sarcoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Germ Cell Cancer 1Osteosarcoma 1

Interventions

temsirolimus 1rofecoxib 1rindopepimut 1ovex 1imetelstat 1entinostat 1cixutumumab 1azurin (50-77) 1Re-Irradiation 1Quality of Life 1Piperazine 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Mebendazole 1Irinotecan 1Immunotherapy 1GRN163L peptide 1Everolimus 1Drug Therapy 1Dasatinib 1Cisplatin 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Stem Neoplasms × Dasatinib × CNS × Clear all
NCT03352427 2022-10-05

Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations

University of Michigan Rogel Cancer Center

Phase 2 Terminated
3 enrolled 7 charts
CNS

Glioma, Brain Stem Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡